Comparison of Fluorescence In-Situ Hybridization (FISH) and Conventional Cytogenetics (CC) in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

被引：0
|
作者：
Aggarwal, G. [1 ]
Manaloor, E. [1 ]
Ramalingam, P. [1 ]
机构：
[1] Med Coll Georgia, Augusta, GA 30912 USA
来源：
LABORATORY INVESTIGATION | 2010年 / 90卷
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
1269
引用
收藏
页码：283A / 283A
页数：1
相关论文
共 50 条
  • [21] Hidden monosomy 7 in acute myeloid leukemia and myelodysplastic syndrome detected by interphase fluorescence in situ hybridization
    Arif, T
    Tanaka, K
    Damodaran, C
    Asou, H
    Kyo, T
    Dohy, H
    Kamada, N
    [J]. LEUKEMIA RESEARCH, 1996, 20 (09) : 709 - 716
  • [22] REDIFINING MONOSOMY 20 BY MOLECULAR CYTOGENETICS IN 1.0 MYELODYSPLASTIC SYNDROMES/ACUTE MYELOID LEUKEMIA (MDS/AML) PATIENTS
    Bernasconi, P.
    Dambruoso, I.
    Boni, M.
    Zappatore, R.
    Cavigliano, P. M.
    Giardini, I.
    Calatroni, S.
    Rocca, B.
    Caresana, M.
    Tarantino, P.
    Lazzarino, M.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 273 - 273
  • [23] TELOMERE/CENTROMERE FLUORESCENCE IN-SITU HYBRIDIZATION (T/C-FISH) IN PATIENTS WITH SECONDARY ACUTE MYELOID LEUKEMIA ARISING FROM MYELODYSPLASTIC SYNDROME WITH COMPLEX KARYOTYPES
    Goehring, G.
    Lange, K.
    Schlegelberger, B.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 289 - 289
  • [24] FLUORESCENCE IN-SITU HYBRIDIZATION (FISH) IMPROVES THE DETECTION OF MONOSOMY-7 IN MYELODYSPLASTIC SYNDROMES (MDS)
    FLACTIF, M
    LAI, JL
    PREUDHOMME, C
    WATTEL, E
    FENAUX, P
    [J]. BLOOD, 1993, 82 (10) : A375 - A375
  • [25] Acquired chromosomal aberrations in children with Down syndrome and myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML)
    Teigler-Schlegel, A
    Baumann, I
    Creutzig, U
    Niemeyer, C
    Harbott, J
    [J]. LEUKEMIA, 2000, 14 (05) : 966 - 966
  • [26] BONE MARROW CONVENTIONAL KARYOTYPING AND FLUORESCENCE IN SITU HYBRIDIZATION (FISH): DEFINING AN EFFECTIVE UTILIZATION STRATEGY FOR THE EVALUATION OF MYELODYSPLASTIC SYNDROME (MDS)
    He, R.
    Wiktor, A. E.
    Kurtin, P. J.
    Van Dyke, D. L.
    Tefferi, A.
    Patnaik, M. S.
    Ketterling, R. P.
    Hanson, C. A.
    [J]. LEUKEMIA RESEARCH, 2015, 39 : S76 - S76
  • [27] Analysis of mutations associated with response to glasdegib in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)
    Ching, Keith A.
    Huang, Donghui
    Wang, Kai
    Ozeck, Mark
    Lira, Paul
    Gao, Jingjin
    Bienkowska, Jadwiga
    Rejto, Paul
    Hardwick, James
    O'Brien, Thomas
    Chan, Geoffrey
    [J]. CANCER RESEARCH, 2018, 78 (13)
  • [28] Lenalidomide and Risk of Acute Myeloid Leukemia (AML) Transformation Among Myelodysplastic Syndrome (MDS) Patients
    Rollison, Dana E.
    Shain, Kenneth H.
    Lee, Ji-Hyun
    Hampras, Shalaka S.
    Fulp, William
    Fisher, Kate
    Al Ali, Najla H.
    Padron, Eric
    Lancet, Jeffrey
    Xu, Qiang
    Knight, Robert D.
    List, Alan F.
    Dalton, William
    Komrokji, Rami
    [J]. BLOOD, 2014, 124 (21)
  • [29] Relationship of progression to acute myeloid leukemia (AML) from myelodysplastic syndrome (MDS) and cytogenetic status
    Hellstrom-Lindberg, E.
    Fenaux, P.
    Mufti, G. J.
    List, A. F.
    Santini, V.
    Gore, S.
    Seymour, J. F.
    Backstrom, J.
    McKenzie, D.
    Beach, C. L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [30] Clinical relevance of circulating myeloperoxidase (MPO) in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)
    Jilani, I
    Vincenti, T
    Faraji, H
    Giles, FJ
    Estey, E
    Kantarjian, HM
    Albitar, M
    [J]. BLOOD, 2004, 104 (11) : 305A - 305A
12345